Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Research group on bone marrow

Dynamic MRI of multiple myelom
© dkfz.de

The research group hemato-oncological imaging deals with the possibilities of non-invasive imaging of the blood forming tissues and the lymphatic system. In particular magnetic resonance imaging (MRI) and computed tomography (CT) are used. The obtained data are correlated with serological, genetic and clinical parameters. We examine whether dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging (DWI) of patients with newly diagnosed multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) help to predict the course of disease. In addition, we are analyzing large patient populations who have been examined with standard imaging methods such as whole-body MRI and whole-body CT in clinical routine. In particular, the transition from early stages of disease - not requiring treatment - to advanced stages will be investigated. In addition, findings of residual disease after therapy are explored for their prognostic significance.
Due to the large amount of data collected we are conducting projects in cooperation with partners from the departments of medical software development to support the analysis of imaging data.
Furthermore, we are currently broadening the spectrum of the studied hemato-oncological diseases and examine for example patients with malignant lymphoma, myelodysplastic syndrome and acute leukemia.

to top
powered by webEdition CMS